Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dafna Gladman

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
Arthritis Care & Research|May 14, 2013
Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trialArthur Kavanaugh, Iain B McInnes, Gerald G Krueger, et al.
RMD Open|November 9, 2023
Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trialVinod Chandran, Vladislav A Malkov, Kaori L Ito, et al.
Frontiers in Immunology|June 17, 2022
Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus NephritisLaura Whittall-Garcia, Kirubel Goliad, Michael Kim, et al.
Rheumatology and Therapy|May 23, 2022
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 TrialsPhilip Mease, Arthur Kavanaugh, Dafna Gladman, et al.
Clinical Chemistry and Laboratory Medicine|October 26, 2012
Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic diseaseAzza Eissa, Daniela Cretu, Antoninus Soosaipillai, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2002
Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C allelesMaureen P Martin, George Nelson, Jeong-Hee Lee, et al.
Journal of Psoriasis and Psoriatic Arthritis|May 22, 2025
Combining Clinical, Genetic and Protein Markers Using Machine Learning Models Discriminates Psoriatic Arthritis Patients From Those With PsoriasisDarshini Ganatra, Max Kotlyar, Amanda Dohey, et al.
The New England Journal of Medicine|October 19, 2017
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF InhibitorsDafna Gladman, William Rigby, Valderilio F Azevedo, et al.
The Journal of Rheumatology|September 9, 2006
Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritisArthur Kavanaugh, Christian Antoni, Philip Mease, et al.
Arthritis Care & Research|March 18, 2015
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled StudyArthur Kavanaugh, Désirée van der Heijde, Anna Beutler, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Arthritis Care & Research|May 14, 2013
Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trialArthur Kavanaugh, Iain B McInnes, Gerald G Krueger, et al.
RMD Open|November 9, 2023
Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trialVinod Chandran, Vladislav A Malkov, Kaori L Ito, et al.
Frontiers in Immunology|June 17, 2022
Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus NephritisLaura Whittall-Garcia, Kirubel Goliad, Michael Kim, et al.
Rheumatology and Therapy|May 23, 2022
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 TrialsPhilip Mease, Arthur Kavanaugh, Dafna Gladman, et al.
Clinical Chemistry and Laboratory Medicine|October 26, 2012
Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic diseaseAzza Eissa, Daniela Cretu, Antoninus Soosaipillai, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2002
Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C allelesMaureen P Martin, George Nelson, Jeong-Hee Lee, et al.
Journal of Psoriasis and Psoriatic Arthritis|May 22, 2025
Combining Clinical, Genetic and Protein Markers Using Machine Learning Models Discriminates Psoriatic Arthritis Patients From Those With PsoriasisDarshini Ganatra, Max Kotlyar, Amanda Dohey, et al.
The New England Journal of Medicine|October 19, 2017
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF InhibitorsDafna Gladman, William Rigby, Valderilio F Azevedo, et al.
The Journal of Rheumatology|September 9, 2006
Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritisArthur Kavanaugh, Christian Antoni, Philip Mease, et al.
Arthritis Care & Research|March 18, 2015
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled StudyArthur Kavanaugh, Désirée van der Heijde, Anna Beutler, et al.
Pageof 9